In the whole DLBCL cohort of 187 patients, SH3BP5 was positive in 60% (103 of 173), with LMO3 positive in 34% (59 of 175) and SNAP25 positive in 46% (77 of 168). The gene discussed is LMO3; the disease is diffuse large B-cell lymphoma.